Octreotide as first-line treatment for women with metastatic breast cancer

被引：0
|
作者：
Ingle, JN
Kardinal, CG
Suman, VJ
Krook, JE
Hatfield, AK
机构：
[1] OCHSNER COMMUNITY CLIN ONCOL PROGRAM,NEW ORLEANS,LA 70121
[2] DULUTH COMMUNITY CLIN ONCOL PROGRAM,DULUTH,MN 55805
[3] COMMUNITY CLIN ONCOL PROGRAM,CARLE CANC CTR,URBANA,IL 61801
来源：
INVESTIGATIONAL NEW DRUGS | 1996年 / 14卷 / 02期
关键词：
octreotide; metastatic breast cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 mu g subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.
引用
收藏
页码：235 / 237
页数：3
相关论文
共 50 条
  • [31] Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer
    Sánchez-Rovira, P
    Jaén, A
    González, E
    Porras, I
    Dueñas, R
    Medina, B
    Mohedano, N
    Fernández, M
    Martos, M
    Lozano, A
    Carrasco, E
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 44 - 47
  • [32] Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
    Gamucci, T.
    D'Ottavio, A. M.
    Magnolfi, E.
    Barduagni, M.
    Vaccaro, A.
    Sperduti, I.
    Moscetti, L.
    Belli, F.
    Meliffi, L.
    BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1040 - 1045
  • [33] Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer
    Robain, M
    Pierga, JY
    Jouve, M
    Asselain, B
    Diéras, V
    Beuzeboc, P
    Palangié, T
    Dorval, T
    Extra, JM
    Scholl, S
    Pouillart, P
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) : 2301 - 2312
  • [34] Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with Metastatic Breast Cancer.
    Schwartzberg, L.
    Rubin, P.
    Patnaik, A.
    Itri, L.
    Olson, A. L.
    Seidman, A. D.
    CANCER RESEARCH, 2011, 71
  • [35] Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer
    Ingle, JN
    Krook, JE
    Mailliard, JA
    Hartmann, LC
    Wieand, HS
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (06): : 498 - 501
  • [36] Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer.
    Schwartzberg, L. S.
    Beeram, M.
    Patnaik, A.
    Tolcher, A. W.
    Itri, L.
    Olson, A. L.
    Seidman, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Rodriguez, R.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A433 - A434
  • [38] Cetuximab for the first-line treatment of metastatic colorectal cancer
    Meads, C.
    Round, J.
    Tubeuf, S.
    Moore, D.
    Pennant, M.
    Baylis, S.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 1 - 8
  • [39] Optimizing the first-line treatment for metastatic colorectal cancer
    Cherri, Sara
    Oneda, Ester
    Zanotti, Laura
    Zaniboni, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Optimizing the first-line treatment for metastatic colorectal cancer
    Ciardiello, Davide
    Petrillo, Angelica
    FRONTIERS IN ONCOLOGY, 2024, 14
12345